Novartis gets FDA Breakthrough Therapy designation for potential prostate cancer drug
177Lu-PSMA-617 is an investigational radioligand therapy intended for metastatic castration-resistant prostate cancer (mCRPC)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Jun 21
177Lu-PSMA-617 is an investigational radioligand therapy intended for metastatic castration-resistant prostate cancer (mCRPC)
11 Jun 21
The approval of Epclusa for younger hepatitis C patients is based on the data from a Phase 2…
10 Jun 21
Trikafta was previously approved in the US to treat cystic fibrosis in 12 years and older people with…
09 Jun 21
Prevnar 20 is the first conjugate vaccine approved to protect against 20 types of invasive pneumococcal diseases and…
08 Jun 21
Aduhelm is said to address a defining pathology of Alzheimer’s disease by reducing amyloid beta plaques in the…
07 Jun 21
The Covid-19 vaccine was already approved in the country for use in adults and adolescents aged 16 years…
04 Jun 21
Lynparza showed clinically meaningful improvement in treating gBRCAm, high-risk, HER2-negative early breast cancer, compared to placebo
03 Jun 21
Opdivo plus Yervoy is approved for use in the 27 member states of the European Union (EU), along…
03 Jun 21
The vaccine has been recommended for use in people aged 18 years and above
02 Jun 21
BridgeBio, through its affiliate QED and partner Helsinn, intends to co-commercialise the cholangiocarcinoma drug in the US